Curium Announces License and Development Agreement With Lantheus for AI-Based PSMA PET Software in Europe
The agreement builds on the existing prostate cancer PSMA-targeted PET imaging collaboration between Curium and Lantheus with an exclusive licensing and development agreement for AI-powered quantitative analysis and standardized reporting of PSMA PET/CT image assessments.
- The agreement builds on the existing prostate cancer PSMA-targeted PET imaging collaboration between Curium and Lantheus with an exclusive licensing and development agreement for AI-powered quantitative analysis and standardized reporting of PSMA PET/CT image assessments.
- Under the terms of the agreement, EXINI’s deep learning platform will be tailored to meet the specific needs of the European market.
- With the expanding treatment options in prostate cancer, including PSMA RLT, there is increasing demand for efficient, standardized quantitative assessment of PSMA disease burden.
- Our partnership with Curium expands the pool of patient data informing our AI algorithm and enables more widespread access to our software.”